Starting Dose of Austedo
Start Austedo at 12 mg per day (either 12 mg once daily for Austedo XR or 6 mg twice daily for standard Austedo tablets), then titrate weekly by 6 mg/day increments based on symptom control and tolerability, up to a maximum of 48 mg/day. 1
Initial Dosing Regimen
The FDA-approved starting approach is straightforward:
- Austedo XR (extended-release): Begin with 12 mg once daily
- Austedo (immediate-release): Begin with 6 mg twice daily (total 12 mg/day)
Both formulations deliver the same total daily dose but differ in administration frequency 1.
Titration Strategy
Weekly dose escalation is the standard approach:
- Increase by 6 mg/day increments each week
- Base increases on two factors: reduction of chorea/tardive dyskinesia AND tolerability
- Maximum recommended dose: 48 mg/day
- Most patients in clinical trials for tardive dyskinesia averaged 38.3 mg/day at optimal dosing 1
Critical Dosing Modifications
Reduce maximum dose to 36 mg/day in these situations:
- Patients taking strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) 1
- Poor CYP2D6 metabolizers 1
For patients with renal/hepatic impairment: The label does not provide specific dose adjustments, but caution is warranted given the drug's metabolism.
Administration Pearls
- Austedo XR: Take with or without food; swallow whole (do not crush, chew, or break)
- Standard Austedo: Take WITH food; swallow whole; doses ≥12 mg/day must be split into twice-daily dosing 1
Switching from Tetrabenazine
If converting from tetrabenazine, use this conversion table 1:
- Tetrabenazine 12.5 mg → Austedo 6 mg once daily
- Tetrabenazine 25 mg → Austedo 12 mg once daily (or 6 mg twice daily)
- Tetrabenazine 50 mg → Austedo 24 mg once daily (or 12 mg twice daily)
- Continue pattern: essentially divide tetrabenazine dose by approximately 2
Treatment Interruption
Less than 1 week off: Resume at previous maintenance dose without re-titration
Greater than 1 week off: Re-titrate from the beginning (start at 12 mg/day) 1
Common Pitfall
The evidence provided includes extensive information about bupropion/dextromethorphan (Auvelity) for depression, which is completely unrelated to Austedo (deutetrabenazine). Austedo is a VMAT2 inhibitor for movement disorders (Huntington's chorea and tardive dyskinesia), not an antidepressant. Do not confuse these medications.
Black Box Warning Consideration
Monitor closely for depression and suicidality, particularly in Huntington's disease patients. Austedo is contraindicated in patients who are actively suicidal or have untreated/inadequately treated depression 1. Screen for psychiatric history before initiating therapy.